PTC News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PTC's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be…

Fisher Asset Management LLC raised its position in shares of PTC Inc. (NASDAQ: PTC) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. T…

BALA CYNWYD, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith…

Data to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly patients with Sarcopenia …

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of PTC Inc. (NASDAQ: PTC) to Schneider Electric for $205.00 per share in cash.Halper Sadeh encourages PTC shareholders t…

While the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street es…

PTC's Q4 fiscal 2026 earnings and revenues beat estimates, while ARR growth remain strong despite revenue declines and divestiture-related pressures.…

PTC Inc. (PTC) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $3.47 per share a year ago.…

Strategic focus on Intelligent Product Lifecycle vision BOSTON, Nov. 4, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2026.…

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a …

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws…

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 20…

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of…

PTC's fiscal Q4 results hinge on ARR growth, AI adoption and cash flow momentum, while its pending $22.6 billion acquisition by Schneider Electric adds a key dimension.…

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Monday, Nov. 16 at 11 …

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its co…

BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith…

Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support IND-Enabling Development …

PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United St…

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue gui…

PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105-trea…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 18. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

